The biologics revenue declined 16 percent driven by negative sales of Infuse in the United States, continuing a downward trend since last summer. The drop was offset partially by revenue growth in other biologics areas.
The international sales for the company’s spine business increased 8 percent. The core spine revenue dropped only 3 percent.
For the full year, Core Spinal revenue reached $2.4 billion, slightly lower than the $2.5 billion reported last year. Spinal biologics revenue also dropped to $800 million for the full-year report.
More Articles on Orthopedic Devices:
Benvenue Medical Appoints 2 New Board Members
Department of Justice Ends 4-Year Investigation of Infuse
AxioMed Receives CE Mark for Freedom Cervical Disc
